Ignite Creation Date:
2024-05-06 @ 2:00 PM
Last Modification Date:
2024-10-26 @ 1:23 PM
Study NCT ID:
NCT04182724
Status:
UNKNOWN
Last Update Posted:
2019-12-03
First Post:
2019-11-27
Brief Title:
Camrelizumab Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer
Sponsor:
Chinese PLA General Hospital
Organization:
Chinese PLA General Hospital
Study Overview
Official Title:
Camrelizumab Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer
Status:
UNKNOWN
Status Verified Date:
2019-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase III Open-label Investigator-initiated Trail of Camrelizumab an Anti-PD-1 Inhibitor Apatinib VEGFR2 Inhibitor and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer The study was designed in two stages the first stage was the tolerance observation stage and the second stage was the curative effect expansion stage
The first part of the study is the Dose-finding Phase designed to establish the safety of Camrelizumab Apatinib and Nab-paclitaxel at different dose Levels125 mgm2 iv q2w 150 mgm2 iv q2w 175 mgm2 iv q2w or 200 mgm2 iv q2w The second part of the study is the Expansion Phase designed to generate additional clinical data at specified doses
This study aims to evaluate the safety and efficacy of Camrelizumab Apatinib and Nab-paclitaxel in the Second-line treatment of advanced Gastric Cancer
The first part of the study is the Dose-finding Phase designed to establish the safety of Camrelizumab Apatinib and Nab-paclitaxel at different dose Levels125 mgm2 iv q2w 150 mgm2 iv q2w 175 mgm2 iv q2w or 200 mgm2 iv q2w The second part of the study is the Expansion Phase designed to generate additional clinical data at specified doses
This study aims to evaluate the safety and efficacy of Camrelizumab Apatinib and Nab-paclitaxel in the Second-line treatment of advanced Gastric Cancer
Detailed Description:
This trial investigated the safety and efficacy of Camrelizumab Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None